Open Access
- research article
- Published by Korean Cancer Association
- Vol. 72 (4), 459-462
- https://doi.org/10.1136/jnnp.72.4.459
Abstract
Objectives: Botulinum toxin type A is a potent neuromuscular paralyzing agent used in various disorders including cervical dystonia. Two preparations of botulinum toxin are now commercially available ( Dysport and Botox), but much controversy remains about their respective potencies. The aim of the study was to compare the efficacy of Botox with two different ratios of Dysport. Methods: A double blind, randomised, three period cross over study involving 54 patients with cervical dystonia was performed. The patients received the following treatments in a randomised order: Botox at the usually effective dose, Dysport at a dose of 1:3 (conversion factor of 3 between Botox and Dysport units—that is, one Botox unit=three Dysport units) and at a dose of 1:4 (conversion factor of four). The improvement of the Tsui (primary outcome criteria) and of the TWSTRS pain scales between baseline and a control visit 1 month after each of the three injections, as well as the incidence of adverse events, were assessed. Results: Comparison of the Tsui scores and of the TWSTRS pain scores showed a better effect on impairment and pain with Dysport 1:3 (p=0.02 and 0.04, respectively) and 1:4 (p=0.01 and 0.02, respectively) than with Botox. The number of adverse events was higher with both Dysport treatments. The most frequent adverse event was dysphagia, found in 3%, 15.6%, and 17.3% (Botox, Dysport 1:3 and 1:4, respectively) of the patients. No adverse event required withdrawal of therapy or specific management. Conclusions: Dysport 1:3 (and Dysport 1:4 to a greater extent) is more efficient than Botox for both impairment and pain in cervical dystonia although with a somewhat higher incidence of minor adverse effects. This strongly suggests that the most appropriate conversion factor between Botox and Dysport units is less than 3 in cervical dystonia.Keywords
This publication has 14 references indexed in Scilit:
- Letters to the EditorMovement Disorders, 1998
- What is the optimal dose of botulinum toxin A in the treatment of cervical dystonia? Results of a double blind, placebo controlled, dose ranging study using DysportJournal of Neurology, Neurosurgery & Psychiatry, 1998
- DYSBOT: A single‐blind, randomized parallel study to determine whether any differences can be detected in the efficacy and tolerability of two formulations of botulinum toxin type A—Dysport and Botox—assuming a ratio of 4:1Movement Disorders, 1997
- Comparison of clinical rating scales in treatment of cervical dystonia with botulinum toxinMovement Disorders, 1997
- The variability in the clinical effect induced by botulinum toxin type A: The role of muscle activity in humansMovement Disorders, 1997
- Dose standardisation of botulinum toxin.Journal of Neurology, Neurosurgery & Psychiatry, 1995
- Therapeutic botulinum toxinThe Lancet, 1994
- Botulinum a toxin for spasmodic torticollis: Multiple vs single injection points per muscleHead & Neck, 1992
- Therapeutic Uses of Botulinum ToxinNew England Journal of Medicine, 1991
- DOUBLE-BLIND STUDY OF BOTULINUM TOXIN IN SPASMODIC TORTICOLLISThe Lancet, 1986